KLK3 and prostate carcinoma: The prostate-specific antigen (PSA), also known as Kallikrein-related peptidase 3 (KLK3), is a single-chain glycoprotein and protease synthesized by the prostate epithelial cells and remains the most evaluated serum biomarker used for early prostate cancer screening, clinical staging, and therapy response monitoring.